Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 13;13:2674. doi: 10.1038/s41467-022-30222-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Schematic diagram of SARS-COV-2 HexaPro-bearing nanoparticle vaccines. Cocktail NP includes the four individual HexaPro-I53-50 NPs from SARS-CoV-2 prototype, B.1.1.7 (Alpha), P.1 (Gamma), and B.1.351 (Beta) variants. Mosaic NP includes the four HexaPro from SARS-CoV-2 prototype, B.1.1.7, P.1, and B.1.351 variants fused to I53-50A1 and assembled with I53-50B.4PT1 in vitro. The figure was created with PyMOL-2.5.2 and UCSF ChimeraX-1.1.1. b Negative-staining electron microscopy images of SARS-CoV-2 HexaPro-based immunogens and individual I53-50 nanoparticles. Scale bar, 200 nm. Similar assay was conducted multiple times to verify the integrity and efficacy of the self-assembled HexaPro-based nanoparticle vaccine. c Immunoprecipitation analysis of purified HexaPro immunogens and SARS-CoV-2 RBD-specific S2-E12 neutralizing monoclonal antibody. IP immunoprecipitation. Similar analysis has beenconducted at least three times. d Size exclusion chromatography profiles of SARS-CoV-2 HexaPro-based nanoparticles and individual I53-50 nanoparticles on a Superose 6 Increase 10/300 GL column. e Dynamic light scattering of SARS-CoV-2 HexaPro-based nanoparticles and individual I53-50 nanoparticles recorded using a Zetasizer Ultra instrument. Source data are provided as a Source Data file.